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Background: Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthesis inhibitor, and insulin
resistance (IR) have been implicated in atherogenesis. Our aim was to estimate relations between ADMA, the
magnitude of IR and angiographic indices of extent and severity of coronary atherosclerosis in non-diabetic men
with stable coronary artery disease (CAD).
Methods: We studied 151 non-diabetic men (mean age 57 ± 11 years) with stable angina, obstructive CAD (at least
1 luminal diameter stenosis of ≥70% in major coronary segments) and without heart failure, and 34 age-matched
controls free of ≥50% coronary narrowings. The following CAD indices were computed: the number of major
epicardial vessels with ≥70% stenosis, Sullivan extent score representing a proportion of the visible coronary tree
with vessel wall irregularities, and Gensini score which reflects both CAD severity and extent, yet assigning a heavier
weight to proximal segments and to the more severe narrowings by a non-linear point system. An estimate of IR
was derived by homeostasis model assessment (HOMA-IR) from fasting insulin and glucose.
Results: Among the CAD patients, the proportions of subjects with 1-vessel, 2- vessel and 3-vessel CAD were 26%,
25% and 49%, respectively. ADMA levels were higher in patients with obstructive CAD compared to the controls
(0.51 ± 0.10 vs. 0.46 ± 0.09 μmol/L [SD], P = 0.01), whereas HOMA-IR was similar (median, 3.2 [interquartile range:
2.4–4.9] vs. 2.9 [2.3–4.7], P = 0.2). Within the CAD group, ADMA increased across ascending quartiles of Sullivan
score (Spearman’s rho = 0.23, P = 0.004), but not with Gensini score (rho = 0.12, P = 0.15) or the number of vessels
involved (rho = 0.08, P = 0.3). ADMA correlated to log-transformed Sullivan score (Pearson's r = 0.21, P = 0.008),
which was only slightly attenuated upon multivariate adjustment (β = 0.19 ± 0.08 [SEM], P = 0.015). HOMA-IR did
not differ according to any measure of angiographic CAD (P ≥ 0.2). ADMA and log (HOMA-IR) were mutually
unrelated (r = 0.07, P = 0.4).
Conclusions: ADMA is associated with diffuse but not focal coronary atherosclerosis in non-diabetic men
with stable CAD irrespectively of the degree of IR. The independent relationship between ADMA and
coronary atherosclerotic burden may contribute to the well-recognized prognostic effect of ADMA in CAD.
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Asymmetric dimethylarginine (ADMA) – an endogen-
ous inhibitor of nitric oxide (NO) formation – has been
implicated in atherogenesis [1,2]. Nevertheless, despite a
bulk of evidence linking ADMA to subclinical carotid
atherosclerosis [3-5] and adverse cardiovascular (CV)
events [6-10], there are inconsistent reports on the
association between ADMA and angiographic coronary
artery disease (CAD). Admittedly, the seminal publica-
tion by Lu et al. [11] and some other studies [10,12,13]
suggested independent relations between elevated
ADMA and the presence or extent of angiographic
CAD. However, according to the largest reports on
ADMA levels in predominantly stable CAD, positive
correlations between ADMA and angiographic CAD
either were absent [14] or lost significance on multi-
variate adjustment [8,9], in contrast to detrimental
prognostic effects of ADMA on CV outcome [8,9,14].
The magnitude of insulin resistance (IR) has been
linked to the incidence of symptomatic CV disease and
adverse outcome [15-19]. It is noteworthy that, using a
mathematical model, Eddy et al. [20] recently estimated
that IR was the most important single cause of
symptomatic CAD being responsible for about 42% of
myocardial infarctions. Nevertheless, like with ADMA,
reports on the relationship of angiographic CAD with IR
or its surrogate measure, fasting insulinemia, are dis-
cordant with negative findings obtained in larger study
groups [21-29]. In addition, there are inconsistent re-
ports on the association between IR and ADMA levels
in various clinical settings [30-43].
To the best of our knowledge, exclusively two studies
examined the relationship of angiographic CAD with
both IR and ADMA. First, our group had previously
described independent and additive effects of a
hyperinsulinemic euglycemic clamp-derived index of IR
and an increased ADMA to L-arginine ratio, but not
ADMA, on the number of major coronary vessels
with >50% narrowings in 53 patients with stable angina
and pre-diabetes [35]. Second, Isiklar et al. [41] have re-
cently observed the lack of correlation between ADMA
and Gensini score in 75 stable angina subjects, including
17 type 2 diabetics. Nevertheless, ADMA was unrelated to
the degree of IR in the both cited studies [35,41].
Therefore, in order to differentiate between the effects
of ADMA and IR on coronary atherosclerosis, we inves-
tigated mutual relations between plasma ADMA, the
degree of IR and angiographic indices of CAD extent
and severity in non-diabetic men with stable CAD.
Methods
Subjects
We studied 151 non-diabetic men (mean age 57 ± 11
years) with stable CAD and significant epicardialcoronary narrowings (at least 1 luminal diameter sten-
osis of ≥70%) who underwent an elective coronary angi-
ography. The current report has been based on the
extension of the previously described group of 80 CAD
patients free of diabetes [43]. In addition, we recruited
34 control men (matched for age and body-mass index)
among patients with suspected CAD who exhibited no
coronary diameter narrowings ≥50%.
Beyond diabetes (diagnosed according to the 2003 rec-
ommendations of the American Diabetes Association by
either fasting glucose or postload glycemia during an
oral glucose tolerance test as mentioned previously
[43]), exclusion criteria – for the both groups – included
heart failure, left ventricular systolic dysfunction (by
ultrasound), congenital heart disease, significant valvular
heart disease, acute coronary syndromes within previous
3 months, any surgery in past 6 months, infections
within previous 2 months, arterial hypertension uncon-
trolled adequately by drugs, overt extracoronary athero-
sclerosis, relevant coexistent diseases, severely decreased
estimated glomerular filtration rate (eGFR) (<30 mL/min
per 1.73 m2 body-surface area according to the simpli-
fied equation developed by the Modification of Diet
in Renal Disease study group [44]), other significant
abnormalities in routine laboratory assays and any
chronic non-CV medication as described earlier in detail
[43,45]. Additionally, all the subjects were receiving an
angiotensin-converting enzyme (ACE) inhibitor, sta-
tin and low-dose aspirin for ≥3 months prior to
index hospitalization [43,45]. In agreement with the
Declaration of Helsinki, the protocol had been ap-
proved by the university ethics committee and each
patient gave informed consent.
Biochemical assays
Peripheral venous blood sampling was performed 0–2 days
before elective coronary angiography, plasma was separated
from ethylenediaminetetraacetic acid-anticoagulated blood
and frozen at −70°C until routine and extended biochem-
ical assays. An index of IR was derived from homeosta-
sis model assessment (HOMA-IR) as a product of
fasting plasma insulin (μU/mL) and glucose (mmol/L)
divided by 22.5 [46].
As described previously [43], plasma ADMA and L-
arginine were determined by a commercially available
enzyme-linked immunosorbent assays (ELISA) (DLD
Diagnostika GmbH., Hamburg, Germany), previously
validated against high-performance liquid chromatog-
raphy coupled to mass spectrometry, the golden stand-
ard for ADMA determinations [47]. According to the
manufacturer, the lower detection limit of ADMA
assay was 0.05 μmol/L and intra-assay and inter-assay
coefficients of variation averaged 7.5 and 10.3%, re-
spectively. Cross-reactivity with L-arginine, symmetric
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<0.02%, 1.2%, and 1.0%, respectively. With regard to L-
arginine, the lower detection limit was 3.0 μmol/L,
intra-assay and inter-assay coefficients of variation av-
eraged 3.6% and 8.3%, respectively, and cross-reactivity
was 0.01% for ADMA and 0.68% for symmetric
dimethylarginine.
Angiographic indices of CAD
Angiographic CAD was quantified by 3 different mea-
sures. First, we computed the number of vessels dis-
eased, i.e., the number of major epicardial coronary
arteries with ≥1 luminal diameter stenosis of ≥70%
(≥50% for the left main coronary artery considered 3-
vessel disease in a left dominant circulation and equiva-
lent to an additional two diseased vessels in a right dom-
inant or balanced circulation) as developed by Ringqvist
et al. [48] on the basis of the Coronary Artery Surgery
Study (CASS). Second, according to Sullivan et al. [49], a
CAD extent score was calculated representing an ap-
proximate proportional length of the visible coronary
vessels with irregularities of the vessel wall [45]. In case
of inadequate collateralization of totally occluded ves-
sels, the mean extent score of the vessel segments prox-
imal to the occlusion was assigned to the occluded
segment. Third, we computed Gensini score which re-
flects both CAD extent and severity assigning a heavier
weight to the more severe luminal narrowings (by a
non-linear point system) and to coronary segments serv-
ing larger regions of the myocardium [50]. All angio-
graphic analyses were performed by a cardiologist
blinded to clinical and biochemical characteristics.
Statistical analysis
Data are shown as mean and SD for normally distributed
continuous variables, median and interquartile range for
not normally distributed values, and numbers with per-
centages for categorical characteristics. The accordance
with a normal distribution was verified by the Lilliefors’
test and logarithmic transformation was applied when
necessary. Intergroup comparisons were performed by
2-sided unpaired Student’s t-test or Fisher’s exact test.
Trend effects according to the number of vessels
diseased or over the quartiles of Gensini and Sullivan
scores were estimated by Spearman’s rank-order correl-
ation coefficient (ρ) for continuous values and the chi-
squared test for trend for categorical data. Bivariate
correlations were assessed by Pearson’s correlation coef-
ficient (r). For multivariate approach, multiple linear re-
gression was applied, including exclusively the covariates
for which the univariate P value was ≤0.15.
Our study design allowed to detect a difference in
mean ADMA concentrations and average HOMA-IR by
0.05 μmol/L and 0.8, respectively (about 0.46 SD),between the CAD subjects with 3-vessel disease com-
pared to those with 1-/2-vessel CAD with a statistical
power of 80% at a type I error rate of 0.05. Additionally,
for the same power and type I error rate, bivariate corre-
lations could be estimated with an r value of 0.225 in
the CAD group as a whole.
Analyses were performed using STATISTICA (data
analysis software system, version 10.0.1011.0; StatSoft,
Inc., Tulsa, OK, USA). A P value <0.05 was inferred
significant.Results
Baseline patients’ characteristics according to
angiographic CAD
Intergroup comparisons are presented in Table 1. The
presence of significant coronary narrowings was associ-
ated with a lower concentration of high-density lipopro-
teins (HDL) cholesterol, marginally reduced eGFR, and a
tendency to higher high-sensitivity C-reactive protein. In
addition, ADMA levels were higher in patients with ob-
structive CAD compared to the controls (0.51 ± 0.10 vs.
0.46 ± 0.09 μmol/L, P = 0.01), whereas HOMA-IR was
similar across the groups (median 3.2 [2.4–4.9] vs. 2.9
[2.3–4.7], P = 0.2) (Table 1).
Among the CAD patients, the proportions of subjects
with 1-vessel, 2- vessel and 3-vessel CAD were 26%, 25%
and 49%, respectively. The median Sullivan score was 29
(20–41) and Gensini score 32 (15–64). Indices of CAD
extent and severity were associated with an older age
(P = 0.01–0.10), depressed eGFR (P = 0.008–0.02), lower
HDL cholesterol (P = 0.0.03–0.14) and a history of
current smoking (P = 0.04–0.12).ADMA and HOMA-IR in relation to angiographic indices
of CAD
ADMA levels increased across ascending quartiles of
Sullivan score (ρ = 0.23, P = 0.004), but not with Gensini
score (ρ = 0.12, P = 0.15) or the number of vessels in-
volved (ρ = 0.08, P = 0.3) (Table 2). L-arginine levels did
not differ between the subgroups irrespective of the cri-
terion used for CAD quantification (P > 0.3).
ADMA correlated to log (Sullivan score) as a continu-
ous variable (r = 0.21, P = 0.008) (Figure 1). By multiple
linear regression with log-transformed Sullivan score as
a dependent variable, the positive association of ADMA
and log (Sullivan score) was only slightly attenuated
upon adjustment for age, HDL cholesterol, eGFR and a
history of current smoking (mean standardized β: 0.19 ±
0.08 [SEM], P = 0.015; adjusted R2: 0.08, P < 0.002).
HOMA-IR did not differ significantly according to any
measure of angiographic CAD (P ≥ 0.2) (Table 2).
ADMA and log-transformed HOMA-IR were unrelated
(r = 0.07, P = 0.4).
Table 1 Baseline characteristics of CAD patients and controls
Variable CAD patients (n = 151) Controls (n = 34) P value
Age (years) 57 ± 11 56 ± 12 0.6
Body-mass index (kg/m2) 27.5 ± 3.8 27.3 ± 3.7 0.8
Current smokers, n (%) 41 (27%) 7 (21%) 0.5
Left ventricular ejection fraction (%) 69 ± 7 70 ± 6 0.4
Hypertension, n (%) 121 (80%) 25 (74%) 0.4
Systolic blood pressure (mm Hg) 130 ± 10 129 ± 12 0.6
Diastolic blood pressure (mm Hg) 79 ± 8 80 ± 9 0.5
Estimated GFR (mL/min per 1.73 m2) 71 ± 10 75 ± 13 0.05
Low-density lipoproteins cholesterol (mmol/L) 2.8 ± 0.7 2.6 ± 0.7 0.3
High-density lipoproteins cholesterol (mmol/L) 0.9 ± 0.3 1.0 ± 0.4 0.02
Triglycerides (mmol/L) 1.5 ± 0.8 1.4 ± 0.7 0.5
High-sensitivity C-reactive protein (mg/L) 1.8 (1.1–3.8) 1.6 (1.0–3.3) 0.07
Glucose (mmol/L) 5.8 ± 0.8 5.6 ± 0.7 0.25
HOMA-IR index 3.2 (2.4–4.9) 2.9 (2.3–4.7) 0.2
ADMA (μmol/L) 0.51 ± 0.10 0.46 ± 0.09 0.01
L-arginine (μmol/L) 70 ± 18 71 ± 17 0.7
Data are shown as mean ± SD, median (interquartile range) or n (%).
Abbreviations: ADMA asymmetric dimethylarginine, CAD coronary artery disease, GFR glomerular filtration rate, HOMA-IR homeostasis model assessment for
insulin resistance.
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Our salient finding was a rise in ADMA with increasing
angiographic CAD extent but not with Gensini score or
the number of major coronary vessels with a significant
stenosis. Additionally, HOMA-IR was unrelated to either
ADMA or any of the measures of angiographic CAD.ADMA versus angiographic CAD
That ADMA concentrations were higher in those with
angiographic obstructive CAD compared to the controls
free of significant CAD, is consistent with 3 out of 5Table 2 ADMA and HOMA-IR according to angiographic CAD
Number of vessels disea
1-vessel CAD (n = 40) 2-vessel CAD (n = 37)
ADMA (μmol/L) 0.49 ± 0.10 0.52 ± 0.11
HOMA-IR 3.3 (2.5–5.0) 3.5 (2.6–5.2)
Sullivan ex
1st quartile ≤20 2nd quartile 21–29
ADMA (μmol/L) 0.48 ± 0.09 0.49 ± 0.08
HOMA-IR 3.0 (2.1–4.5) 3.1 (2.7–4.9)
Gensin
1st quartile <15 2nd quartile 15–32
ADMA (μmol/L) 0.49 ± 0.10 0.51 ± 0.10
HOMA-IR 3.1 (2.1–4.6) 3.3 (2.6–5.1)
Data are shown as mean ± SD or median (interquartile range).
Abbreviations: ADMA asymmetric dimethylarginine, CAD coronary artery disease, GFR
insulin resistance.largest reports on ADMA in relation to angiographic
CAD [7-10,14].
Meinitzer et al. [8] reported a univariate, but not
multivariate, association of ADMA with Friesinger
score in 2,543 participants of the Ludwigshafen Risk
and Cardiovascular Health (LURIC) study (60% with
stable CAD) with coronary stenoses ≥20%, nevertheless,
Friesinger score is more strongly influenced by the se-
verity and number of coronary narrowings than by CAD
extent [51]. Lu et al. [10] observed higher ADMA with
increasing maximal stenosis (<20% vs. 20–49% vs. ≥50%)
in major coronary arteries by both univariate andindices
sed
3-vessel CAD (n = 74) P for trend
0.50 ± 0.10 0.3
3.0 (2.0–4.6) 0.6
tent score
3rd quartile 30–41 4th quartile >41 P for trend
0.52 ± 0.10 0.54 ± 0.11 0.004
3.5 (2.7–5.4) 3.1 (2.3–4.8) 0.2
i score
3rd quartile 33–64 4th quartile >64 P for trend
0.50 ± 0.11 0.52 ± 0.12 0.15
3.0 (2.2–5.2) 3.2 (2.5–4.8) 0.4
glomerular filtration rate, HOMA-IR homeostasis model assessment for
Figure 1 A positive correlation between plasma levels of asymmetric dimethylarginine (ADMA) and log-transformed Sullivan score of
the extent of coronary atherosclerosis. r, Pearson’s correlation coefficient.
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antly stable angina, which was yet limited to 638 non-
diabetics. In 1,011 subjects undergoing elective coronary
angiography, Wang et al. [9] reported elevated ADMA
in the presence of ≥1 coronary stenosis of ≥50% and/or
history of myocardial infarction or coronary revasculari-
zation. However, those authors [9,10] treated patients
with a coronary diameter stenosis of ≥50% as a single
group, whereas in the present study subjects with ob-
structive CAD were further discriminated according to
the number of vessels involved and the Gensini and
Sullivan scores.
On the other hand, in 1,364 patients, mainly non-
diabetics with stable angina, Borgeraas et al. [14] re-
cently reported even lower ADMA levels in subjects
with significant CAD, which is contradictory to our find-
ings. Nevertheless, they also observed no relationship
between ADMA and the presence of 3-vessel CAD [14],
in accordance with our data. Finally, as Schnabel et al.
[7] did not list any measure of angiographic CAD among
covariates associated with ADMA in 1,874 CAD patients
from the AtheroGene study, it can possibly be suspected
that those correlations were statistically insignificant.
Similarly, Siegerink et al. [52] have not presented data
on the relationship between angiographic variables and
ADMA in 1,148 subjects with stable CAD participating
in the KAROLA (“Langzeitfolge der KARdiOLogischen
Anschlussheilbehandlung”) study.
Therefore, our findings suggest of a link between
ADMA and diffuse, not focal, coronary atherosclerosis.
As most acute coronary syndromes occur due to plaque
rupture with superimposed occlusive thrombosis at sitesinvolving non-obstructive coronary narrowings [53-56],
this concept might explain significant independent asso-
ciations of ADMA with adverse outcome but not with
indices of CAD severity (the presence of angiographic-
ally obstructive CAD [9] or Friesinger score [8]) upon
multivariate adjustment for traditional risk factors, renal
function and C-reactive protein in the previously cited
reports on patients referred to coronary angiography
[8,9]. In keeping with this hypothesis, Bigi et al. [57]
demonstrated that an angiographic extent score pro-
vided an additional prognostic information beyond the
number of coronary lesions of ≥70% in 228 stable CAD
subjects over a mean follow-up of 30 months. Further-
more, an association of elevated ADMA with the risk of
myocardial infarction was found even by Borgeraas et al.
[14] despite lower ADMA levels in subjects with signifi-
cant CAD as mentioned previously.
Insulin resistance versus angiographic CAD
The lack of correlation between HOMA-IR and angio-
graphic CAD is contradictory to reports on a positive
relationship between angiographic CAD extent and IR –
assessed by the insulin suppression test or HOMA-IR –
which was observed in small groups (n = 38–83) of
non-diabetic subjects with stable CAD [23,24,26]. Addition-
ally, we have previously found that the magnitude of inte-
grated insulin response to an oral glucose tolerance test, a
surrogate measure of IR [58], was related to multivessel
CAD in 52 non-diabetic men below 50 years of age, which
was absent in older subjects [59].
On the other hand, Vonbank et al. [28] observed no
difference in HOMA-IR between subgroups of 986
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ography divided according to the presence or number of
lumen narrowings of ≥50%, irrespective of diabetes sta-
tus. Accordingly, that the lack of a positive association
between angiographic CAD and HOMA-IR was also
reported in an adequately powered study [28],
strengthens our negative findings. It is noteworthy that a
negative result had been previously described in 797
men by Solymoss et al. [22] who related the number of
coronary arteries with ≥50% stenosis to fasting
insulinemia, a surrogate marker of IR. Although An
et al. [29] identified HOMA-IR as an independent pre-
dictor of one-year coronary atherosclerosis progression
in 366 CAD subjects, however, Gensini score at baseline
did not correlate to HOMA-IR, in agreement with our
results.
Nevertheless, a recent meta-analysis involving over
500,000 subjects without diabetes, mainly without
prevalent atherosclerotic CV disease at baseline,
proved the ability of HOMA-IR to predict incident
CV events with a 46% increase in the relative risk of
symptomatic CAD per 1-SD increment in HOMA-IR
[19]. This was consistent with the independent
association of HOMA-IR and CV mortality in 5,511
nondiabetic, adult participants of the third U.S.
National Health and Nutrition Examination Survey
(NHANES III) during a mean follow-up of 8.5 years
[18]. Furthermore, Tenenbaum et al. [17] confirmed
an independent adverse prognostic effect of HOMA-
IR in 2,938 patients with preexisting CAD over a
mean follow-up of 6.2 years. However, it is note-
worthy that in 5,464 participants of Multi-Ethnic
Study of Atherosclerosis (MESA) free of prevalent
atherosclerotic CV disease the prognostic effect of
HOMA-IR on the incidence and progression of
coronary artery calcification over a 1.6–3.2-year
follow-up disappeared after adjustment upon the
components of the metabolic syndrome, lying down-
stream of IR [60].
Accordingly, it was hypothesized that the detrimen-
tal prognostic value of HOMA-IR in non-diabetic
CAD patients even after controlling for the presence
of the metabolic syndrome [61] or its traits [17,62]
might rather be attributable to the precipitation of
acute CV events than to the slow progression of
coronary atherosclerosis [28]. In addition, a role of
IR in the development of restenosis after coronary
stenting has also been suggested [63,64]. Therefore,
this concept is analogous to the previously pro-
posed hypothesis suggestive of the mechanisms
other than ADMA being a correlate of more severe
coronary atherosclerosis as an explanation of the
well-recognized ability of ADMA to predict adverse
outcome in CAD [7-10,14].Insulin resistance in relation to the L-arginine–NO–
ADMA pathway
In our hands, HOMA-IR and ADMA were independent
of each other, confirming an earlier analysis in a sub-
group of the study patients [43]. Stühlinger et al. [31]
were the first to report a positive association between
ADMA levels and the magnitude of IR in hypertensive
and normotensive subjects, which precipitated the
notion of ADMA as a common contributor to IR and
endothelial dysfunction [65], an antecedent of coronary
plaques [66,67]. In that seminal study IR was quantified
as a steady-state plasma glucose concentration during
simultaneous infusions of insulin, glucose and a somato-
statin analogue, i.e., insulin suppression test [31]. Intri-
guingly, in spite of experimental evidence supporting
mechanistic links between ADMA and IR within the
liver and the skeletal muscle [68], the majority of clinical
studies ‒ except for Marliss et al. [34] ‒ revealed no rela-
tionship of ADMA and the insulin-mediated glucose
uptake during a hyperinsulinemic euglycemic clamp
[30,35,69,70], the golden standard method for IR assess-
ment. Additionally, inconsistent results were obtained when
IR was represented by HOMA-IR or a steady-state plasma
glucose during the insulin suppression test with either posi-
tive [32,33,38,42] or lacking [36,37,39] relations between IR
and ADMA.
On the other hand, the magnitude of IR was linked to
a polymorphism in the gene encoding one of isoforms of
dimethylarginine dimathylaminohydrolase (DDAH-2)
[40], an enzyme controlling the majority of ADMA ca-
tabolism [71]. In an animal study circulating ADMA, in
contrast to endothelial function, was related to the
activity of DDAH-1 but not DDAH-2 [72], the latter be-
ing predominant in the vascular endothelium [73]. Ac-
cordingly, the link between circulating ADMA and the
degree of IR could be obscured by the inability of plasma
ADMA to reflect its intracellular level in endothelial
cells, which had previously been suggested by Maas
et al. [74] as an explanation for the lack of correlation
between plasma ADMA and polymorphisms in the pro-
moter region of the DDAH-2 gene that were related to
the prevalence of hypertension.
Irrespective of mutual relations between ADMA and IR,
their differential associations with the generation and/or
bioavailability of NO, an endogenous antiatherogenic mol-
ecule, appear relevant in terms of atherogenesis. Accord-
ingly, that in our patients angiographic CAD extent was
correlated to ADMA, but not IR, is compatible with the re-
cent report by Tessari et al. [75] who demonstrated that
ADMA but not IR was a negative modulator of whole-
body NO generation in subjects with atherosclerotic risk
factors. Admittedly, previous studies suggested a coupling
of insulin metabolic sensitivity to insulin’s vascular effects
and endothelial function [76-78]. However, although
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also evidence supporting the dissociation between, on the
one side, insulin’s ability to stimulate glucose uptake, and,
on the other side, insulin’s vasodilatory action as well as
NO formation or bioavailability both at baseline and under
hyperinsulinemic conditions [30,79-81]. That Natali et al.
[82] recently observed a deterioration in glucose tolerance
but no changes in the magnitude of peripheral IR on acute
inhibition of NO synthesis in non-diabetic subjects, is also
consistent with the notion of IR-independent effects of NO
deficiency.
Finally, in addition to the putative ability of ADMA to
impair NO generation, other potential mechanisms of
proatherogenic ADMA activity were recently suggested,
such as an association of ADMA with increased arterial
stiffness described in prediabetic subjects [83] and pa-
tients on maintenance hemodialysis [84]. Although per-
ipheral blood pressure was similar in our CAD subjects
and controls, however, elevated central arterial pressure
in the presence of higher ADMA could have contributed
to coronary atherosclerosis.
Study limitations
First, the number of participants was relatively small and
the number of subjects in the control group was over 4-
fold lower compared to the CAD group. Nevertheless,
we applied a wide set of exclusion criteria in order to re-
strict the sources of interindividual variability within our
study groups. Second, ADMA levels can be influenced
by medications, especially ACE inhibitors [85] and pos-
sibly some statins [73]. However, the ability of this effect
to interfere with the associations of ADMA with angio-
graphic CAD was probably limited because we had in-
cluded exclusively patients who were receiving ACE
inhibitors and statins for ≥3 months prior to blood
withdrawal for ADMA assay. Third, the magnitude of IR
was estimated by HOMA, whereas a hyperinsulinemic
euglycemic clamp is the golden standard for IR quantifi-
cation. Furthermore, Reaven [86] recently raised con-
cerns with regard to using HOMA-IR as a measure of
IR when altered insulin clearance considerably affects
changes in fasting insulinaemia, which was shown on
acute NO formation blockade [82]. This limitation con-
strains conclusions based on HOMA-IR in our previous
study [43] and also the present one, all the more because
interindividual differences in ADMA could influence
NO bioavailability [87]. Nonetheless, for feasibility rea-
sons, we were not able to perform the clamps in a series
of CAD patients referred to diagnostic coronary
angiography.
Conclusions
In summary, ADMA levels appear to reflect diffuse but
not focal coronary atherosclerosis in non-diabetic menwith stable CAD irrespective of the magnitude of impaired
metabolic sensitivity to insulin. Hence, the independent as-
sociation between ADMA and coronary atherosclerotic
burden may contribute to the well-recognized prognostic
effect of ADMA in CAD.
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